LONGi and ENGIE Forge Powerful Partnership to Drive Solar Innovation with Hi-MO 9 BC Technologyby krapalmMay 7, 2025PR Newswire
SGS & Co and SGK unite to become Propelis – a global agency built for brand impactby krapalmMay 7, 2025PR Newswire
Ricoh named as a Leader in IDC MarketScape Worldwide Hardcopy Remanufacturing 2025 Vendor Assessmentby krapalmMay 7, 2025PR Newswire
“Human Creativity is Inspired by Abstract Connections That AI Cannot Intuitively Make”by krapalmMay 7, 2025PR Newswire
New Akamai Study Reveals API Security Incidents Cost APAC Enterprises Over US$580,000 on Average in the Past Yearby krapalmMay 7, 2025PR Newswire
PEC Ltd. US$160 million buyout and privatization by Liberty Energy Solutions Ltdby krapalmMay 7, 2025PR Newswire
PEC Ltd. US$160 million buyout and privatization by Liberty Energy Solutions Ltdby krapalmMay 7, 2025PR Newswire
TIER IV fuels development of autonomous driving standards and an open dataset in Japanese government initiativeby krapalmMay 7, 2025PR Newswire
Citi and SDX Join Forces to Unlock Access to Tokenized Private Market Assets for Global Issuers and Investorsby krapalmMay 7, 2025PR Newswire
Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edemaby krapalmMay 7, 2025PR Newswire
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACRby krapalmMay 7, 2025PR Newswire
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.by krapalmMay 7, 2025PR Newswire
FancyTech Closes Series B+ to Power AI Personalized Content Solutions in Thailand and Southeast Asiaby krapalmMay 7, 2025PR Newswire
FancyTech ปิดรอบระดมทุน Series B+ เพื่อขับเคลื่อนโซลูชันคอนเทนต์แบบปรับเปลี่ยนได้ด้วย AI ในประเทศไทยและเอเชียตะวันออกเฉียงใต้by krapalmMay 7, 2025PR Newswire
Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progressionby krapalmMay 7, 2025PR Newswire
